|
US7037916B2
(en)
*
|
1999-07-15 |
2006-05-02 |
Pharmacopeia Drug Discovery, Inc. |
Pyrimidine derivatives as IL-8 receptor antagonists
|
|
GB0016877D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
|
AU2002316421B2
(en)
*
|
2001-06-26 |
2008-05-15 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-ALPHA expression
|
|
IL161663A0
(en)
*
|
2001-11-01 |
2004-09-27 |
Janssen Pharmaceutica Nv |
AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
PT1497019E
(pt)
|
2002-04-23 |
2015-09-10 |
Bristol Myers Squibb Co |
Compostos de pirrolotriazina anilina úteis como inibidores de quinase
|
|
TW200306841A
(en)
|
2002-04-23 |
2003-12-01 |
Bristol Myers Squibb Co |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
JP2006508997A
(ja)
*
|
2002-11-28 |
2006-03-16 |
シエーリング アクチエンゲゼルシャフト |
Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
|
|
MXPA05006367A
(es)
*
|
2002-12-12 |
2005-08-29 |
Pharmacia Corp |
Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
|
|
US6909001B2
(en)
|
2002-12-12 |
2005-06-21 |
Pharmacia Corporation |
Method of making tricyclic aminocyanopyridine compounds
|
|
WO2004069829A1
(en)
*
|
2003-01-10 |
2004-08-19 |
Pharmacopeia Drug Discovery, Inc. |
(2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis
|
|
MXPA05007485A
(es)
|
2003-01-14 |
2006-01-30 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
|
|
EP1927594A1
(en)
*
|
2003-01-14 |
2008-06-04 |
Arena Pharmaceuticals, Inc. |
1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
UA92450C2
(ru)
*
|
2003-01-14 |
2010-11-10 |
Арена Фармасьютикалз, Инк. |
1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия
|
|
JP2006516653A
(ja)
|
2003-02-05 |
2006-07-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
キナーゼ阻害剤ピロロトリアジンの製造方法
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
EP2385041B1
(en)
*
|
2003-05-01 |
2013-09-18 |
Bristol-Myers Squibb Company |
Pyrazole-amine compounds useful as kinase inhibitors
|
|
US7652044B2
(en)
*
|
2003-06-03 |
2010-01-26 |
Novartis A.G. |
P-38 inhibitors
|
|
US7465738B2
(en)
|
2003-06-16 |
2008-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as promoters of SMN2
|
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
AR045047A1
(es)
*
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
PT1660458E
(pt)
*
|
2003-08-15 |
2012-04-27 |
Novartis Ag |
2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
|
|
TWI258478B
(en)
|
2003-10-31 |
2006-07-21 |
Arena Pharm Inc |
Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
|
|
EP1687274A1
(en)
*
|
2003-11-20 |
2006-08-09 |
Warner-Lambert Company LLC |
Androgen receptor modulators
|
|
US7459562B2
(en)
*
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
|
US7754714B2
(en)
*
|
2004-05-18 |
2010-07-13 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl substituted pyrimidinediamine compounds and their uses
|
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
|
PL1756084T3
(pl)
*
|
2004-06-04 |
2009-06-30 |
Arena Pharm Inc |
Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie zaburzeń z metabolizmem związanych
|
|
TW200600513A
(en)
*
|
2004-06-30 |
2006-01-01 |
Bristol Myers Squibb Co |
A method for preparing pyrrolotriazine compounds
|
|
US7253167B2
(en)
*
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
|
TW200618803A
(en)
|
2004-08-12 |
2006-06-16 |
Bristol Myers Squibb Co |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
|
CA2581454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
Reddy Us Therapeutics, Inc. |
Novel pyrimidine compounds, process for their preparation and compositions containing them
|
|
EP1794135A1
(en)
*
|
2004-09-27 |
2007-06-13 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
GB2420559B
(en)
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
|
SI1814878T1
(sl)
|
2004-11-24 |
2012-06-29 |
Rigel Pharmaceuticals Inc |
Spojine spiro-2,4-pirimidindiamina in njihova uporaba
|
|
MY148521A
(en)
*
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US20060247263A1
(en)
*
|
2005-04-19 |
2006-11-02 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
US8153791B2
(en)
*
|
2005-12-21 |
2012-04-10 |
Janssen Pharmaceutica N.V. |
Substituted pyrimidinyl oxime kinase inhibitors
|
|
US8278446B2
(en)
*
|
2005-12-21 |
2012-10-02 |
Janssen Pharmaceutica N.V. |
Process for preparing substituted diaminopyrimidine oximes
|
|
WO2007081630A2
(en)
*
|
2005-12-21 |
2007-07-19 |
Janssen Pharmaceutica, N.V. |
Substituted pyrimidinyl kinase inhibitors
|
|
US8013153B2
(en)
*
|
2006-03-23 |
2011-09-06 |
Janssen Pharmaceutica, N.V. |
Substituted pyrimidine kinase inhibitors
|
|
EP2441757A1
(en)
|
2006-07-31 |
2012-04-18 |
Praecis Pharmaceuticals Incorporated |
Aurora kinase inhibitors from an encoded small molecule library
|
|
EP2059512A1
(en)
*
|
2006-08-01 |
2009-05-20 |
Praecis Pharmaceuticals Incorporated |
P38 kinase inhibitors
|
|
ES2555803T3
(es)
|
2006-10-23 |
2016-01-08 |
Cephalon, Inc. |
Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
|
|
WO2008135786A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Astrazeneca Ab |
Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
|
|
CN101903357A
(zh)
*
|
2007-07-17 |
2010-12-01 |
里格尔药品股份有限公司 |
作为pkc抑制剂的环状胺取代的嘧啶二胺
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
MX2010009159A
(es)
|
2008-02-22 |
2010-09-14 |
Rigel Pharmaceuticals Inc |
Uso de 2,4-pirimidindiaminas para el tratamiento de aterosclerosis.
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US20110245156A1
(en)
*
|
2008-12-09 |
2011-10-06 |
Cytokine Pharmasciences, Inc. |
Novel antiviral compounds, compositions, and methods of use
|
|
AT509266B1
(de)
*
|
2009-12-28 |
2014-07-15 |
Univ Wien Tech |
Substituierte pyridine und pyrimidine
|
|
KR20120114355A
(ko)
*
|
2010-01-13 |
2012-10-16 |
글락소스미스클라인 엘엘씨 |
화합물 및 방법
|
|
ES2577829T3
(es)
|
2010-06-04 |
2016-07-19 |
F. Hoffmann-La Roche Ag |
Derivados de aminopirimidina como moduladores de la LRRK2
|
|
EP3323818A1
(en)
|
2010-09-22 |
2018-05-23 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
|
NO2638031T3
(enExample)
|
2010-11-10 |
2018-03-10 |
|
|
|
NZ627896A
(en)
|
2012-01-27 |
2016-11-25 |
Biomarin Technologies B V |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
CN102952084A
(zh)
*
|
2012-11-15 |
2013-03-06 |
大连九信生物化工科技有限公司 |
一种4，6－二氯－2－甲硫基－5－硝基嘧啶的合成方法
|
|
US9556126B2
(en)
|
2013-12-20 |
2017-01-31 |
Signal Pharmaceuticals, Llc |
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
|
|
PL3242666T3
(pl)
|
2015-01-06 |
2025-02-17 |
Arena Pharmaceuticals, Inc. |
Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
|
|
BR112017027656B1
(pt)
|
2015-06-22 |
2023-12-05 |
Arena Pharmaceuticals, Inc. |
Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
|
|
US20190060286A1
(en)
|
2016-02-29 |
2019-02-28 |
University Of Florida Research Foundation, Incorpo |
Chemotherapeutic Methods
|
|
PL3442947T3
(pl)
*
|
2016-04-15 |
2023-10-02 |
Epizyme, Inc. |
Związki arylowe lub heteroarylowe podstawione aminą jako inhibitory ehmt1 i ehmt2
|
|
MX2019009841A
(es)
|
2017-02-16 |
2020-01-30 |
Arena Pharm Inc |
Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
|
|
WO2019016111A1
(en)
*
|
2017-07-18 |
2019-01-24 |
Lonza Ltd |
PROCESS FOR THE PREPARATION OF CHLORINATED S-PROPYLTHIOBARBITURIC ACID
|
|
BR112020006677A2
(pt)
|
2017-10-05 |
2020-10-06 |
Fulcrum Therapeutics, Inc. |
uso de inibidores p38 para reduzir a expressão de dux4
|
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
|
CA3102136A1
(en)
|
2018-06-06 |
2019-12-12 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
PE20220597A1
(es)
|
2019-05-10 |
2022-04-22 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
|
|
US11518758B2
(en)
|
2019-05-10 |
2022-12-06 |
Deciphera Pharmaceuticals, Llc |
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
PE20221083A1
(es)
|
2019-06-17 |
2022-07-05 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
|